Rodent Cell, Per Se Patents (Class 435/352)
  • Publication number: 20110287429
    Abstract: Methods for propagating haploid genomes of male or female origina and genetic screening and modification thereof are provided. These haploid genomes may be used to produce haploid embryos, and embryonic stem-like cells and differentiated cells. Also, these haploid genomes and cells containing, may be used as nuclear transfer donors to produce diploid nuclear transfer units. These diploid NT units e.g., human NT units, may be used to obtain pluripotent cells and differentiated cells and tissues.
    Type: Application
    Filed: January 28, 2011
    Publication date: November 24, 2011
    Inventors: James M. Robl, Pedro Moreira
  • Publication number: 20110275569
    Abstract: A protein inhibitor from Sulfolobulus Solfataricus and peptides thereof, which both have the ability to inhibit AARE and elastase. Similarly to the eukaryotic counterparts, the recombinant protein is able to inhibit in vitro the bovine alfa-chymotrypsin with a high specificity, and the porcine elastase but not all commercial available trypsins, features which distinguish all the members belonging to the family PEBP. Through site-specific mutagenesis techniques of the gene codifying SsCEI, it has been recognized the “reactive site loop”—RCL—on the inhibitor, responsible for the interaction with the eukarial protease target already identified. The inhibitor and the peptides thereof can be used as new compounds capable of modulating cognitive enhancement cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases.
    Type: Application
    Filed: April 25, 2011
    Publication date: November 10, 2011
    Applicant: CONSIGLIO NAZIONALE DELLE RICERCHE
    Inventors: Mosé ROSSI, Gianna PALMIERI, Giuliana CATARA, Ruvo MENOTTI
  • Publication number: 20110275121
    Abstract: The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consisting of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.
    Type: Application
    Filed: May 27, 2009
    Publication date: November 10, 2011
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Fang Jin, Richard N. Harkins, Maxine Bauzon, Terry Hermiston
  • Publication number: 20110274623
    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: April 29, 2011
    Publication date: November 10, 2011
    Inventor: Steven Jacobs
  • Publication number: 20110269119
    Abstract: Methods and apparatus are disclosed herein for encoding human readable text conveying a non-genetic message into nucleic acid sequences with a substantially reduced probability of biological impact and decoding such text from nucleic acid sequences. In one embodiment, each symbol of a symbol set of human readable symbols uniquely maps to a respective codon identifier. Mapping may ensure that each symbol will not map to a codon identifier that generates an amino acid residue which has a single-letter abbreviation that is the equivalent to the respective symbol. Synthetic nucleic acid sequences comprising such human readable text, and recombinant or synthetic cells comprising such sequences are provided, as well as methods of identifying cells, organisms, or samples containing such sequences.
    Type: Application
    Filed: October 29, 2010
    Publication date: November 3, 2011
    Applicant: Synthetic Genomics, Inc.
    Inventors: Clyde A. Hutchison, Michael G. Montague, Hamilton O. Smith
  • Publication number: 20110269174
    Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.
    Type: Application
    Filed: June 15, 2011
    Publication date: November 3, 2011
    Applicant: Immune Disease Institute, Inc.
    Inventors: Anjana RAO, Stefan Feske, Patrick Hogan, Yousang Gwack
  • Publication number: 20110263484
    Abstract: The present invention relates to single chain Fc Type III Interferon fusion proteins and methods of using same. The single chain Fc Type III Interferon fusion proteins comprise at least one Type III Interferon, two Fc regions and at least one linker, can be produced in a variety of single chain configurations, and are effector function minus or have a substantially reduced effector function.
    Type: Application
    Filed: October 13, 2009
    Publication date: October 27, 2011
    Inventors: Margaret D. Moore, Michael G. Dodds, Paul O. Sheppard, Henrik Andersen
  • Publication number: 20110262591
    Abstract: The present invention relates to novel polynucleotide sequences comprising genes that encode novel lipolytic enzymes, as well asfunctional equivalents of the gene or the amino acid sequences with high homology thereto. The invention also relates to methods of using these lipolytic enzymes in industrial processes, for example in the dairy or baking industry.
    Type: Application
    Filed: February 26, 2009
    Publication date: October 27, 2011
    Inventors: Jan Metske Laan Van Der, Yulia M. Efimova, Karin Turk, Albertus Alard Van Dijk, Natalja Alekseevna Cyplenkova, Margot Elisabeth Francoise Schooneveld-Bergmans, Arie Gerrit Terdu, Arjen Sein
  • Publication number: 20110265198
    Abstract: Disclosed herein are methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a DNA binding domain and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Application
    Filed: April 25, 2011
    Publication date: October 27, 2011
    Inventors: Philip D. Gregory, Michael C. Holmes
  • Publication number: 20110263027
    Abstract: Adeno-associated virus 7 sequences, vectors containing same, and methods of use are provided.
    Type: Application
    Filed: November 14, 2007
    Publication date: October 27, 2011
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Publication number: 20110262402
    Abstract: Provided is a pharmaceutical composition and a method for the treatment and/or prophylaxis of arthritis, inter alia, rheumatoid arthritis. The pharmaceutical composition comprises human mesenchymal stem cells, and the method comprises administering an effective amount human mesenchymal stem cells to a patient.
    Type: Application
    Filed: September 4, 2008
    Publication date: October 27, 2011
    Inventors: Masahiko Kuroda, Masakatsu Takanashi, Katsuko Sudo, Shigeki Yamauchi, Hiroyuki Shirono, Toru Hirado, Kenichi Maeda
  • Publication number: 20110262944
    Abstract: The present invention aims to express influenza virus RNA polymerase on a large scale, to crystallize the influenza virus RNA polymerase, and to provide a method for screening a substance capable of serving as an active ingredient in anti-influenza drugs. The present invention provides a complex comprising a polypeptide consisting of an amino acid sequence at positions 678-757 of the RNA polymerase PB1 subunit in influenza A/Puerto Rico/8/34 H1N1 and a polypeptide consisting of an amino acid sequence at positions 1-37 of RNA polymerase PB2 subunit in influenza A/Puerto Rico/8/34 H1N1. This complex can be crystallized in the presence of a precipitant such as potassium phosphate and PEG4000. Moreover, with the use of information on the crystal structure of this complex, it is possible to provide a method for screening a substance capable of serving as an active ingredient in anti-influenza drugs.
    Type: Application
    Filed: October 16, 2009
    Publication date: October 27, 2011
    Applicant: UNIVERSITY OF TSUKUBA
    Inventors: Eiji Obayashi, Sam-Yong Park, Kyosuke Nagata, Atsushi Kawaguchi
  • Publication number: 20110256586
    Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
    Type: Application
    Filed: June 24, 2011
    Publication date: October 20, 2011
    Inventors: Joan C. Egrie, Steven G. Elliott, Jeffrey K. Browne, Karen C. Sitney
  • Patent number: 8039256
    Abstract: To efficiently select and proliferate the mesenchymal stem cells without necessity of an exclusive separating device and a complicated separating operation, mesenchymal stem cells are cultured by seeding at least one of a bone marrow solution, an umbilical cord blood, a peripheral blood, a synovial membrane and an amniotic membrane in a liquid culture medium which is filled in a vessel, includes water as its main components and having a specific gravity between 1.06 and 1.10 at 37° C., and making a culture at a temperature 37±2° C. on a ceiling side surface of the vessel, preferably the specific gravity being regulated by use of at least one selected from silica fine powder coated by polyvinyl pyrrolidone, a water soluble copolymer of sucrose and epichlorohydrin, and a water soluble compound including a triiodo aromatic ring.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: October 18, 2011
    Assignees: GC Corporation, Two Cells Co., Ltd.
    Inventors: Yuhiro Sakai, Katsuyuki Yamanaka, Mika Takeda, Tomohisa Okura, Koichiro Tsuji
  • Publication number: 20110250692
    Abstract: The present invention relates to a method for producing mammalian induced pluripotent stem cells, comprising introducing mammal-derived reprogramming factors comprising Oct3/4 and Nanog, or nucleic acids encoding Oct3/4 and Nanog, into mammal-derived somatic cells and thereby inducing induced pluripotent stem cells from the somatic cells, wherein the reprogramming factors comprise neither Sox2 nor nucleic acid encoding Sox2.
    Type: Application
    Filed: October 30, 2009
    Publication date: October 13, 2011
    Applicant: KYOTO UNIVERSITY
    Inventors: Shinya Yamanaka, Koji Tanabe
  • Publication number: 20110236363
    Abstract: Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and/or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor/stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications.
    Type: Application
    Filed: September 11, 2009
    Publication date: September 29, 2011
    Inventors: Lung-Ji Chang, Ekta Samir Patel
  • Publication number: 20110236435
    Abstract: A method for growing bone cells. In one aspect, the present invention provides a method for growing bone cells, comprising the steps of (a) anodizing a titanium substrate to form an array of titanium dioxide nanotubes on a surface of the titanium substrate, (b) subjecting the anodized titanium substrate to a radio frequency plasma discharge to chemically modify the array of titanium dioxide nanotubes formed on the surface of the titanium substrate, (c) seeding bone cells onto the surface of the titanium substrate that has an array of titanium dioxide nanotubes thereon after the subjecting step, and (d) incubating the seeded bone cells for a period of time effective for the cells to grow and proliferate.
    Type: Application
    Filed: March 25, 2011
    Publication date: September 29, 2011
    Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventor: Alexandru S. Biris
  • Publication number: 20110230642
    Abstract: The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells. By using IGF particularly in conjunction with HSA in the culture medium after recloning, the recloning efficiency and hence the quantity of clones obtained can be increased significantly.
    Type: Application
    Filed: March 16, 2009
    Publication date: September 22, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Juergen Fieder, Lore Florin, Hitto Kaufmann, Thomas Krieg, Melanie Briegel
  • Publication number: 20110217772
    Abstract: The present invention relates to animal protein free cell culture media comprising a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components.
    Type: Application
    Filed: May 6, 2011
    Publication date: September 8, 2011
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Manfred Reiter, Wolfgang Mundt, Leopold Grillberger, Barbara Kraus
  • Publication number: 20110212164
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described.
    Type: Application
    Filed: May 2, 2011
    Publication date: September 1, 2011
    Applicant: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan BARNETT, Jan Zur Megede
  • Publication number: 20110200579
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO57290 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as cardiovascular, endothelial or angiogenic disorders; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; or developmental abnormalities.
    Type: Application
    Filed: January 22, 2008
    Publication date: August 18, 2011
    Applicants: Genentech, Inc., Lexicon Pharmaceuticals, Inc
    Inventors: Jaime-Jo Cunningham, Peter Vogel
  • Publication number: 20110195455
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: April 4, 2011
    Publication date: August 11, 2011
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Patent number: 7993876
    Abstract: The invention relates to a DNA sequence that encodes a polypeptide with phospholipase activity and was isolated from Aspergillus and sequences derived therefrom, polypeptides with phospholipase activity encoded by these sequences as well as the use of these polypeptides for degumming of vegetable oil, for the preparation of dough and/or bakery products, for the preparation of dairy products, for processing steps in the textile industry and for related applications.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: August 9, 2011
    Assignee: AB Enzymes GmbH
    Inventors: Khanh Q. Nguyen, Volker Marschner, Kornelia Titze, Bruno Winter
  • Publication number: 20110191865
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Application
    Filed: June 3, 2009
    Publication date: August 4, 2011
    Applicants: Genentech, Inc., Lexicon Genetics Incorporated
    Inventors: Joel A. Edwards, Wenhu Huang, Charles A. Montgomery, Ni Nancy Qian, Zheng-Zheng Shi, Mary Jean Sparks, Peter Vogel, Mindy Westbrook
  • Patent number: 7985587
    Abstract: The invention features methods of promoting hair growth in a subject. The methods include inducing or mimicking the effects of Wnt promoted signal transduction, e.g., by increasing the level of Wnt protein or administering an agent which mimics an effect of Wnt promoted signal transduction, e.g., by administering lithium chloride. Methods of inhibiting hair growth are also provided.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: July 26, 2011
    Assignee: The General Hospital Corporation
    Inventors: Bruce A. Morgan, Jiro Kishimoto, Robert Burgeson
  • Publication number: 20110179505
    Abstract: The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e.g. cancer, and with a modified FGFR4.
    Type: Application
    Filed: September 29, 2009
    Publication date: July 21, 2011
    Applicant: MAX-PLANCK-GESELLSCHAGFT zur FOERDERUNG der WISSENSCHAFTEN e.V.
    Inventors: Axel Ullrich, Thomas Mayer, Sylvia Streit, Nina Seitzer
  • Publication number: 20110177600
    Abstract: The subject invention provides a site-specific integration system and methods for generating eukaryotic cells lines for protein production. The provided system includes a first site-specifically integrating target vector and a second site-specifically integrating donor vector comprising a gene of interest. Also provided are mammalian cell lines produced by the subject methods and systems, as well as kits that include the subject systems.
    Type: Application
    Filed: May 22, 2007
    Publication date: July 21, 2011
    Inventors: William J. Rutter, Michele P. Calos, Jimmy Z. Zhang
  • Publication number: 20110171729
    Abstract: The invention provides a novel method for generating stable mammalian cell lines with enhanced protein production capabilities, and to expression vectors and related methods for high level expression of biopharmaceutical proteins of interest.
    Type: Application
    Filed: May 3, 2007
    Publication date: July 14, 2011
    Applicant: AB MAXIS INC.
    Inventors: Kevin Caili Wang, Shengjiang Kiu
  • Publication number: 20110171730
    Abstract: The present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.
    Type: Application
    Filed: December 21, 2010
    Publication date: July 14, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Robert McKay, Brett P. Monia, Brenda F. Baker, Namir Sioufi
  • Publication number: 20110159541
    Abstract: Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Application
    Filed: January 27, 2011
    Publication date: June 30, 2011
    Inventors: Trevor Collingwood, Gregory J. Cost
  • Publication number: 20110142845
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
    Type: Application
    Filed: September 13, 2010
    Publication date: June 16, 2011
    Applicant: Abbott Laboratories
    Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
  • Publication number: 20110144043
    Abstract: The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders.
    Type: Application
    Filed: December 11, 2009
    Publication date: June 16, 2011
    Applicant: Dana-Farber Cancer Institute
    Inventor: David A. Frank
  • Publication number: 20110136689
    Abstract: The present invention provides a dual expression vector, and methods for its use, for the expression and secretion of a full-length polypeptide of interest in eukaryotic cells, and a soluble domain or fragment of the polypeptide in bacteria. When expressed in bacteria, transcription from a bacterial promoter within a first intron and termination at the stop codon in a second intron results in expression of a fragment of the polypeptide, e.g., a Fab fragment, whereas in mammalian cells, splicing removes the bacterial regulatory sequences located in the two introns and generates the mammalian signal sequence, allowing expression of the full-length polypeptide, e.g., IgG heavy or light chain polypeptide. The dual expression vector system of the invention can be used to select and screen for new monoclonal antibodies, as well as to optimize monoclonal antibodies for binding to antigenic molecules of interest.
    Type: Application
    Filed: January 26, 2011
    Publication date: June 9, 2011
    Applicant: MacroGenics, Inc.
    Inventors: Leslie Sydnor Johnson, Ling Huang
  • Patent number: 7951588
    Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: May 31, 2011
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Sham-Yuen Chan, Hsinyi Yvette Tang, Yiwen Tao, Yongjian Wu, Ruth Kelly
  • Publication number: 20110104754
    Abstract: We describe a method of growing an animal cell in a culture medium, in which the culture medium comprises an elevated concentration of a thymidine family member, in which the growth or viability of the animal cell is increased as a result of the elevated concentration of the thymidine family member in the cell culture medium. Preferably, the cell culture medium comprises a semi-solid medium, which is a serum free or chemically defined medium.
    Type: Application
    Filed: January 11, 2011
    Publication date: May 5, 2011
    Inventors: Irene Bramke, Julian Francis Burke
  • Patent number: 7919674
    Abstract: It is an object of the present invention to provide a high affinity antibody effective as a diagnostic or therapeutic for various diseases; a transgenic mammal for producing the high affinity antibody; and a medicine comprising the high affinity antibody or a cell producing the high affinity antibody. According to the present invention, a transgenic mammal carrying a GANP gene transferred thereinto, its progeny, or a part thereof, and a method of producing a high affinity antibody using the same are provided.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: April 5, 2011
    Assignee: Immunokick Incorporation
    Inventor: Nobuo Sakaguchi
  • Publication number: 20110076681
    Abstract: Methods and means for efficiently downregulating the expression of a target gene of interest in cell from an organism that is an animal, fungus, and protest. The invention provides chimeric nucleic acid molecules for downregulating target genes. The invention also provides modified cells and organisms comprising the chimeric nucleic acid molecules and compositions comprising the chimeric molecules.
    Type: Application
    Filed: March 31, 2010
    Publication date: March 31, 2011
    Inventors: Peter Michael Waterhouse, Linda Jane Lockett, Ming-Bo Wang, Timothy James Doran, Robert John Moore, Gerald Wayne Both
  • Publication number: 20110059525
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.
    Type: Application
    Filed: June 17, 2010
    Publication date: March 10, 2011
    Applicant: INTREXON CORPORATION
    Inventors: SUBBA REDDY PALLI, MARIANNA ZINOVJEVNA KAPITSKAYA, DEAN ERVIN CRESS
  • Publication number: 20110061114
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245, PRO246, PRO258, PRO287, PRO328, PRO344, PRO357, PRO526, PRO724, PRO731, PRO732, PRO1003, PRO1104, PRO1151, PRO1244, PRO1298, PRO1313, PRO1570, PRO1886, PRO1891, PRO4409, PRO5725, PRO5994, PRO6097, PRO7425, PRO10102, PRO10282, PRO61709 or PRO779 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Application
    Filed: November 12, 2010
    Publication date: March 10, 2011
    Inventors: JOEL A. EDWARDS, Charles Montgomery, Zheng-Zheng Shi, Mary Jean Sparks
  • Publication number: 20110052549
    Abstract: Methods and compositions for aligning cell growth is provided by this invention by contacting at least one isolated cell with a device, wherein the device comprises a plurality of continuously orientating substantially parallel structures on the surface of the device, and culturing the cell under conditions that favor division of the at least one cell into a population of cells, thereby growing the population of cells in a substantially parallel orientation.
    Type: Application
    Filed: August 26, 2010
    Publication date: March 3, 2011
    Inventors: Wei-Chun Chin, Tzu-I Chao, Eric Yi-Tong Chen, Chi-Shuo Chen
  • Publication number: 20110052634
    Abstract: The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions.
    Type: Application
    Filed: July 23, 2010
    Publication date: March 3, 2011
    Inventors: Scott C. Weaver, Ilya V. Frolov, Elena Frolova
  • Publication number: 20110053222
    Abstract: Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PCS, are provided. In one embodiment PCS is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid.
    Type: Application
    Filed: July 21, 2010
    Publication date: March 3, 2011
    Inventors: Robert T. PETERS, Alan J. Bitonti
  • Publication number: 20110039330
    Abstract: The present invention provides serum-free cell culture media formulations which are capable of supporting the in vitro cultivation of animal cells. The media comprise at least one nutrient of non-animal derivation, such as at least one plant peptide and/or at least one non-animal or plant lipid and/or fatty acid. The media may further optionally comprise an enzymatic digest or extract of yeast cells. The present invention also provides methods of cultivating animal cells in vitro using these cell culture media formulations. In addition, the media of the present invention can be used for growth of animal cells for virus production.
    Type: Application
    Filed: April 14, 2010
    Publication date: February 17, 2011
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Paul PRICE, Steve Gorfien, Douglas Danner, Mark Plavsic
  • Publication number: 20110041191
    Abstract: The present invention relates to a transgenic animal suitable for modelling Alzheimer's Disease. The present invention also relates to cells and gametes of the transgenic animal of the invention, along with nucleic acids and vectors suitable for generating the transgenic animal. Methods of generating the transgenic animal are also described, along with screening methods utilizing the transgenic animal.
    Type: Application
    Filed: July 9, 2010
    Publication date: February 17, 2011
    Inventors: Bettina Platt, Gernot Riedel
  • Publication number: 20110030072
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins.
    Type: Application
    Filed: July 23, 2010
    Publication date: February 3, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • Publication number: 20110023151
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding ABC transporter proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding ABC transporter proteins.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • Publication number: 20110023148
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with addiction disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence encoding addiction-related proteins and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for addiction and withdrawal side effects and other effects.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • Publication number: 20110023150
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences associated with schizophrenia. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence associated with schizophrenia and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences associated with schizophrenia.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • Publication number: 20110020811
    Abstract: Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided.
    Type: Application
    Filed: May 21, 2010
    Publication date: January 27, 2011
    Applicant: Amgen Inc.
    Inventor: Christopher K. Crowell
  • Publication number: 20110023153
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study AD development and methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons